By Digifin Pty Ltd · About this coverage
Key Points
- Exclusive co-develop and co-promote deal with Alentis for lixudebart in rare kidney and liver disease
- Initial payment US$355m; up to US$1.2bn further commercial milestones for Alentis
- CSL funds Phase 2/3 AAV-RPGN work and Phase 2 FSGS and PSC trials
- Global commercial profits to be shared 55% CSL / 45% Alentis once commercialised
About CSL (ASX:CSL)
CSL Limited is an ASX-listed biotechnology company headquartered in Melbourne. It collects human plasma and manufactures plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders and other rare and serious conditions, alongside iron deficiency and nephrology medicines and seasonal influenza vaccines.
CSL (ASX:CSL) entered an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for rare kidney and liver disease.
Lixudebart is in an ongoing Phase 2 trial in ANCA-associated vasculitis and rapidly progressive glomerulonephritis (AAV-RPGN). CSL will pay Alentis an initial US$355 million, with Alentis eligible for up to an additional US$1.2 billion in commercial milestone payments. CSL will fully fund completion of the ongoing Phase 2 RENAL trial and a planned Phase 3 trial in AAV-RPGN, Phase 2 trials in focal segmental glomerulosclerosis and primary sclerosing cholangitis, and other supporting development. Once commercialised, global profits will be shared 55% to CSL and 45% to Alentis. The parties also plan to advance lixudebart in FSGS and PSC. The release does not disclose expected trial readout timing or regulatory filing dates.
Source: CSL Limited (ASX:CSL), 5 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.